Impax extends expiration dates for certain lots of epinephrine injection
Impax Laboratories, a subsidiary of Amneal Pharmaceuticals, announced that in collaboration with the U.S. Food and Drug Administration, the company is extending the expiration dates for certain lots of its epinephrine injection, USP auto-injector, 0.15 mg and 0.3 mg, the authorized generic of Adrenaclick. Based on the medical necessity of epinephrine auto-injector and to assist with any shortages, the expiration date for specific lots will be increased from 18 months to 20 months. By allowing use of certain lots of epinephrine injection, USP auto-injector for two months beyond their labeled expiration dates, the FDA seeks to ensure adequate supply of epinephrine products in the marketplace. To help ensure patient safety, the FDA advises that supplies of epinephrine injection, USP auto-injector should have been - and should continue to be - stored as labeled.